See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
|Articles|June 21, 2011
- Summer 2011
- Volume 10
- Issue 2
From Our Archives: Art & Healing
Advertisement
You can read more art and healing articles from CURE's archive:
Art and Life (Winter 2007)
A program in New York City helps survivors use artistic expression to communicate their experiences...
Figurative Testimonials (Spring 2008)
In June 2003, artist Karen Starrett Belfer was diagnosed with stage 3 ovarian cancer. To cope with her cancer experience, she turned to her art, which, she says, helps her process and make visible hidden emotions...
Articles in this issue
about 15 years ago
Blog: Standing up to melanomaabout 15 years ago
From Our Archives: Advance Directiveabout 15 years ago
Teenage Tan Bans Spreading Across Statesabout 15 years ago
Prostate Cancer Prevention Drugs Get a “No” Voteabout 15 years ago
The Health Care Law: Rhetoric and Realityover 15 years ago
Nonmelanoma Skin Cancerover 15 years ago
From Our Archives: Skin Cancerover 15 years ago
Risky Infectionsover 15 years ago
Scarred, Scared, SacredAdvertisement
Related to this article
Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.
After cancer, taking time to rest and travel can create space to heal, reconnect and remember that life is about more than simply surviving.
Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.
Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
Advertisement
Advertisement